Related Experiment Video

Updated: Jun 21, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction

Angelo Modica1, Fredrik Karlsson, Thomas Mooe

  • 1Department of Internal Medicine, Section of Cardiology, Ostersund Hospital, Ostersund, Sweden. angelo.modica@jll.se.

Thrombosis Journal
|July 9, 2009
PubMed

Insights

Elevated peak C-reactive protein (CRP) after myocardial infarction predicts new cardiovascular events. However, platelet aggregation and PFA-100 closure times do not independently predict these events.

Area of Science:

  • Cardiology
  • Biomarkers
  • Clinical Research

Background:

  • Recurrent cardiovascular events are common after acute myocardial infarction (AMI).
  • Evaluating prognostic markers is crucial for patient outcomes.
  • Platelet function and inflammation are key factors post-AMI.

Purpose of the Study:

  • To assess the impact of platelet aggregation, PFA-100 closure times, and peak C-reactive protein (CRP) on cardiovascular events after AMI.
  • To investigate the relationship between platelet function tests and peak CRP levels.

Main Methods:

  • A study included 334 patients with AMI.
  • Platelet aggregation was measured using an aggregometer (PA-200).
  • High residual platelet reactivity was defined by normal PFA-100 closure times during aspirin therapy.

Main Results:

  • The highest quartile of peak CRP was linked to a 2.0-fold increased risk of death, myocardial infarction, or ischemic cerebral events.
  • Elevated peak CRP correlated with increased platelet aggregation and high residual platelet reactivity.
  • Neither heightened platelet aggregation nor high residual platelet reactivity independently predicted new cardiovascular events.

Conclusions:

  • Peak CRP levels are associated with new cardiovascular events in AMI patients.
  • While peak CRP relates to platelet function, pronounced platelet aggregation or PFA-100 closure times do not independently predict adverse events.
Abstract

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...